Literature DB >> 8098013

Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas.

M al-Kasspooles1, J H Moore, M B Orringer, D G Beer.   

Abstract

Esophageal cancer is one of the 10 most prevalent human cancers worldwide. The incidence of esophageal adenocarcinoma is on the rise and patients with this disease typically have very poor prognosis. Informative biomarkers would benefit the clinical management of this disease. We examined 13 cases with esophageal adenocarcinomas and 5 cases with Barrett's esophagus for amplification of the EGFR and erbB-2 genes. We detected multiple copies of the EGFR gene in 30.8% of the tumors and multiple copies of the erbB-2 gene in 15.4% of the tumors. Of the cases with amplification of the erbB-2 gene, co-amplification of the EGFR gene was found. Multiple copies of the EGFR gene were also found in one case of Barrett's esophagus. Immunohistochemical staining of the tissues revealed increased expression of the erbB-2 protein in Barrett's mucosa and adenocarcinoma, but no associations between staining intensity and degree of EGFR or erbB-2 gene amplification, histology, or tumor stage were found. Differential polymerase chain reaction was examined as a method for pre-operative detection of gene amplification in esophageal tumors and Barrett's mucosa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098013     DOI: 10.1002/ijc.2910540209

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  53 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

3.  Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.

Authors:  Taher Abu Hejleh; Barry R Deyoung; Eric Engelman; Jeremy M Deutsch; Bridget Zimmerman; Thorvardur R Halfdanarson; Daniel J Berg; Kalpaj R Parekh; William R Lynch; Mark D Iannettoni; Sudershan Bhatia; Gerald Clamon
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

4.  Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).

Authors:  Michael K Gibson; Paul Catalano; Lawrence R Kleinberg; Charles A Staley; Elizabeth A Montgomery; Antonio Jimeno; Wei Frank Song; Mary F Mulcahy; Lawrence P Leichman; Al B Benson
Journal:  Oncologist       Date:  2019-06-21

5.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

6.  Mitigating fluorescence spectral overlap in wide-field endoscopic imaging.

Authors:  Chenying Yang; Vivian Hou; Leonard Y Nelson; Eric J Seibel
Journal:  J Biomed Opt       Date:  2013-08       Impact factor: 3.170

7.  Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.

Authors:  K Specht; T Richter; U Müller; A Walch; M Werner; H Höfler
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

8.  Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.

Authors:  R Langer; B H A Von Rahden; J Nahrig; C Von Weyhern; R Reiter; M Feith; H J Stein; J R Siewert; H Höfler; M Sarbia
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

9.  Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.

Authors:  Tomislav Dragovich; Christopher Campen
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

10.  Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.

Authors:  Agnieszka M Rygiel; Francesca Milano; Fiebo J Ten Kate; Jacques J G H M Bergman; Kausillia K Krishnadath
Journal:  J Oncol       Date:  2010-06-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.